A multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging
Open Access
- 21 February 2026
- journal article
- case report
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (5) , 2095-2100
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of War
- Sontag Foundation
- National Brain Tumor Society
- National Cancer Institute
- National Institute of General Medical Sciences
This publication has 15 references indexed in Scilit:
- Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomasNeuroradiology, 2024
- FDA approves first IDH-targeted glioma drugNature Biotechnology, 2024
- A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsThe Lancet Oncology, 2023
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaNew England Journal of Medicine, 2023
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialNature Medicine, 2023
- Conventional MRI features can predict the molecular subtype of adult grade 2–3 intracranial diffuse gliomasNeuroradiology, 2022
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch signEuropean Radiology, 2019
- The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation studyNeuro-Oncology, 2018
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016